---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010609"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:30:32.243901+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M

## Summary
- BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.
- Phase 2 program to start in 2023: two studies in breast, colorectal, endometrial, and gastroesophageal cancers.
- Entered clinical supply agreement with Roche for pertuzumab (Perjeta) to combine with BDC-1001 in breast cancer.
- Cash, cash equivalents, and marketable securities of $192.8M as of Dec 31, 2022, expected to fund operations through 2025.
- Full-year 2022 collaboration revenue $5.7M; R&D expenses $73.1M; loss from operations $90.3M.

## SEC filing metadata
- accession: 0000950170-23-010609
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/0000950170-23-010609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/bolt-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010609
- JSON: https://secwatch.observer/filing/0000950170-23-010609.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010609.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended
  - Result: reported results
  source text: – 5:00 p.m. EDT Location: Orange County Convention Center, Section 24 Fourth Quarter and Full Year 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended December 31, 2022, compared to $0.5 million and $1.3 million for the same quarter and year in 2021. The collaboration
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/0000950170-23-010609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.